Significance of monitoring trough plasma concentration levels for invasive fungal infection prophylaxis with itraconazole oral solution in patients with hematological malignancies: a prospective study

Ichiro Kawano, Kana Matsumoto, Takashi Jiromaru, Fumiaki Jinnochi, Yuichiro Semba, Takeshi Sugio, Keiji Sakamoto, Noriyuki Saito, Shuro Yoshida, Hideho Henzan, Ken Takase, Kunihiko Morita, Tetsuya Eto

研究成果: ジャーナルへの寄稿学術誌査読

抄録

In this prospective study, we examined the prophylactic effect of itraconazole oral solution (ITCZ-OS) against invasive fungal disease in hematologic malignancy patients. The participants were 36 patients, at least 16 years of age, with hematologic malignancies treated at our hospital. ITCZ-OS 200 mg/day was administered orally twice a day with a target trough plasma concentration of 350 ng/ml. If the patient did not achieve the target trough plasma concentration, the dose was increased. The success rate of achieving the target trough plasma concentration of ITCZ with a dose of 200 mg/day was 63.9%. During the observation period, 2 patients (5.6%) were diagnosed with possible invasive fungal disease according to the EORTC/MSG 2008 criteria. Adverse events were observed in 2 patients (5.6%). The results showed administration of ITCZ-OS while monitoring ITCZ trough plasma concentrations to be effective for preventing invasive fungal disease, and no serious adverse events occurred. Since predicting trough levels in response to ITCZ administrations is difficult, its measurement is necessary to maintain the prophylactic effect of ITCZ.

本文言語英語
ページ(範囲)2475-2480
ページ数6
ジャーナル[Rinsho ketsueki] The Japanese journal of clinical hematology
57
12
DOI
出版ステータス出版済み - 1月 1 2016
外部発表はい

!!!All Science Journal Classification (ASJC) codes

  • 医学一般

フィンガープリント

「Significance of monitoring trough plasma concentration levels for invasive fungal infection prophylaxis with itraconazole oral solution in patients with hematological malignancies: a prospective study」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル